Insulet (NASDAQ:PODD) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Insulet (NASDAQ:PODD) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $1.66 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.21, FiscalAI reports. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.17 EPS. Insulet updated its FY 2026 guidance to 6.460- EPS.

Here are the key takeaways from Insulet’s conference call:

• Strong second-quarter performance: Revenue increased 23% on a constant-currency basis to $802 million, while adjusted operating margin expanded 140 basis points to 19.3% and adjusted EPS rose 41.5% to $1.66.
• Insulet lowered its 2026 outlook to 20%–22% total company revenue growth and 17%–19% U.S. Omnipod growth, citing weaker-than-expected type 2 customer retention and utilization, slower new customer starts, and somewhat lower anticipated pricing.
• The company is expanding customer support, revising sales-force incentives to emphasize retention, refining sampling, and scaling Omnipod Discover to improve onboarding and retention during the critical first 90 days of therapy.
• International momentum remains strong, with full-year international Omnipod growth guidance raised to 30%–32%; the company also reported coverage additions for 6.5 million lives and reduced prior-authorization barriers for approximately 10 million lives.
• Insulet continues to invest in its pipeline, including Omnipod 6 and a fully closed-loop type 2 system, with a 510(k) submission for the latter still expected in 2027; formal 2027 guidance and an updated long-range outlook will come with fourth-quarter results.

Insulet Stock Performance

Shares of PODD stock traded down $32.91 during trading hours on Wednesday, reaching $133.91. 5,905,849 shares of the company’s stock were exchanged, compared to its average volume of 1,289,715. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company’s 50 day moving average is $155.82 and its two-hundred day moving average is $196.09. The company has a market cap of $9.27 billion, a P/E ratio of 30.99, a price-to-earnings-growth ratio of 1.18 and a beta of 1.10. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently made changes to their positions in the stock. RTW Investments LP purchased a new stake in shares of Insulet during the 4th quarter worth approximately $92,264,000. AQR Capital Management LLC lifted its stake in Insulet by 161.6% in the 4th quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock valued at $130,499,000 after buying an additional 283,643 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Insulet in the second quarter worth $80,082,000. Squarepoint Ops LLC boosted its stake in shares of Insulet by 11,905.8% during the third quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after acquiring an additional 225,377 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in Insulet by 37.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after purchasing an additional 156,009 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PODD. Piper Sandler decreased their price objective on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Sanford C. Bernstein decreased their price target on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Barclays dropped their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Finally, Raymond James Financial set a $216.00 price target on Insulet in a report on Monday, June 8th. Twenty analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $233.38.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet exceeded second-quarter expectations, reporting adjusted earnings of $1.66 per share versus the $1.44–$1.45 consensus estimate. Revenue increased 23.5% year over year, and the company reportedly surpassed expectations across key operating metrics. Insulet Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management highlighted continued growth in the Omnipod business and maintained full-year earnings guidance near $6.46 per share, suggesting profitability remains solid despite the softer sales outlook. Insulet Corporation 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Several law firms reminded investors of an August 31 deadline to seek lead-plaintiff status in a securities class action covering purchasers from February 21, 2025, through May 26, 2026. These notices largely repeat previously reported litigation rather than represent a new operational development. PODD Investor Reminder
• Negative Sentiment: Insulet reduced its full-year 2026 revenue outlook to approximately $3.2 billion–$3.3 billion, below the roughly $3.3 billion analyst consensus. Third-quarter revenue guidance of $829.9 million–$844.0 million also trails the $846.3 million estimate, reflecting slower U.S. insulin-pump sales. Insulet Cuts Sales Growth Forecast
• Negative Sentiment: Reports indicate some Type 2 diabetes patients discontinue Omnipod before 90 days, raising concerns about adoption, retention and the potential size of this growth opportunity. Insulet Beats Q2 but Cuts Guidance
• Negative Sentiment: Oppenheimer downgraded Insulet (PODD) from “outperform” to “market perform,” signaling reduced conviction in near-term upside after the guidance cut. Insulet Downgrade
• Negative Sentiment: Multiple securities-fraud complaints allege that Insulet and executives misrepresented manufacturing quality and product safety before two Omnipod medical-device corrections. The allegations could increase legal costs and damage investor confidence, although they remain unproven. Insulet Class Action Filed

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.